APDS Prevalence Uncertainty And Pipeline Delays Will Test Long-Term Rare Disease Thesis

AnalystLowTarget

Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

07 Jan 26

Updated

10 Jul 26

Views

Not Invested

Shared on 10 Jul 26

Fair value Increased 17%

PHARM: Pediatric APDS Approval And EU Launch Plans Will Drive Rerating

Regulators are moving Joenja closer to use in younger children in the U.S., and the first EU launch is on the calendar, setting up two fresh ways the drug could reach more patients. The rollout still depends on an approval decision and country-by-country access talks, but expectations are already shifting around how fast the business can grow.

16 views

Fair Value vs Share Price

€2

vs €0.8855.8% undervalued

3.1%

Revenue growth

1.1%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Pharming Group

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Flawless balance sheet with reasonable growth potential.

Market cap€624.8m

PB2.7x

Estimated Growth13.3%

Dividend YieldN/A

Full analysis

CEO & management

Fabrice Chouraqui

CEO

2.9yrs

CEO Tenure

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.